News Humanigen facing bankruptcy as reverse merger fails Three years ago, Humanigen was riding high with a COVID-19 therapy in late-stage testing and shares worth upwards of $20 apiece.
News Eyeing emergency use of COVID-19 drug, Humanigen partners wi... Humanigen is hoping for emergency use authorisation in the US for an antibody to treat severe COVID-19 before the end of 2020, and has teamed up with Swiss contract manufacturer Lonza to ma
News Anavex sinks after pulling Alzheimer's filing in EU Shares in Anavex Life Sciences lost more than a third of their value today after the company abandoned an EU filing for its Alzheimer's therapy.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
